Chronic lymphocytic leukemia and related disorders - Clinical


On-demand
English
Poster Presentation
11 June 2021 9:00 AM - 9:00 AM


Presentations

Title Time Appointment
EP631 (EP631) OTHER MALIGNANCIES IN THE HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE, MULTICENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY
11 June 2021 9:00 AM - 9:00 AM
EP632 (EP632) VENETOCLAX-OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION-BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY
11 June 2021 9:00 AM - 9:00 AM
EP633 (EP633) PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
11 June 2021 9:00 AM - 9:00 AM
EP634 (EP634) MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB (IBR) TO VENETOCLAX (VEN) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPROVE STUDY
11 June 2021 9:00 AM - 9:00 AM
EP635 (EP635) REAL-WORLD APPLICATION OF NATIONAL COMPREHENSIVE CANCER NETWORK CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) FOR CLL/SLL FROM THE INFORMCLL REGISTRY
11 June 2021 9:00 AM - 9:00 AM
EP636 (EP636) IBRUTINIB TREATMENT IN THE FIRST-LINE SETTING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UP TO 7 YEARS OF FOLLOW-UP IN THE RESONATE-2 STUDY
11 June 2021 9:00 AM - 9:00 AM
EP637 (EP637) SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS
11 June 2021 9:00 AM - 9:00 AM
EP638 (EP638) TG-1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND LYMPHOMA
11 June 2021 9:00 AM - 9:00 AM
EP639 (EP639) ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: 34-MONTH FOLLOW-UP RESULTS
11 June 2021 9:00 AM - 9:00 AM
EP640 (EP640) CONDITIONAL RELATIVE SURVIVAL AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS
11 June 2021 9:00 AM - 9:00 AM
EP642 (EP642) PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB
11 June 2021 9:00 AM - 9:00 AM
EP643 (EP643) A PHASE 1A/B DOSE ESCALATION STUDY OF THE MUTATION AGNOSTIC BTK/FLT3 INHIBITOR LUXEPTINIB (CG-806) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES
11 June 2021 9:00 AM - 9:00 AM
EP644 (EP644) TEN-YEAR FOLLOW-UP OF 415 CLL PATIENTS TREATED WITH FLUDARABINE CYCLOPHOSPHAMIDE-BASED CHEMOIMMUNOTHERAPY IN THE FRONTLINE ARCTIC AND ADMIRE TRIALS, A COMPREHENSIVE ASSESSMENT OF PROGNOSTIC FACTORS
11 June 2021 9:00 AM - 9:00 AM
EP645 (EP645) OUTCOME OF 100 TP53-DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED FRONT-LINE WITH IBRUTINIB. A REAL-LIFE CAMPUS CLL STUDY.
11 June 2021 9:00 AM - 9:00 AM
EP646 (EP646) REAL-WORLD EFFICACY AND SAFETY OF VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA – FIRST DATA FROM THE VERONE STUDY, IN PATIENTS WITH VENETOCLAX MONOTHERAPY
11 June 2021 9:00 AM - 9:00 AM
EP647 (EP647) POTENTIAL CAPABILITIES OF MRNA ROR1 AND MIR-155 FOR MRD ASSESSMENT IN CLL
11 June 2021 9:00 AM - 9:00 AM
EP648 (EP648) SAFETY AND EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY CLL TREATED UNDER REAL-LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVE
11 June 2021 9:00 AM - 9:00 AM
EP649 (EP649) COMPARISON OF VENETOCLAX INPATIENT AND OUTPATIENT RAMP-UP STRATEGIES FOR CLL. UK MULTICENTRE RESTROSPECTIVE STUDY
11 June 2021 9:00 AM - 9:00 AM
EP650 (EP650) MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB IN RICHTER TRANSFORMATION OF CLL: SAFETY INTERIM ANALYSIS
11 June 2021 9:00 AM - 9:00 AM
EP651 (EP651) TREATMENT OF CLL RELAPSED/REFRACTORY PATIENTS IN COVID-19 PANDEMIC: A REAL-LIFE EXPERIENCE WITH VENETOCLAX-RITUXIMAB COMBINATION IN SOUTHERN ITALY.
11 June 2021 9:00 AM - 9:00 AM
EP652 (EP652) LEUKEMIA CUTIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO)
11 June 2021 9:00 AM - 9:00 AM
EP654 (EP654) EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP
11 June 2021 9:00 AM - 9:00 AM